BioSpace News Archive

Genalyte, a leading diagnostics and analytics company, announced the closure of $50 million in financing.

ZIVO Bioscience, Inc. announces that in its recent analysis of two poultry studies performed at separate research facilities, ZIVO product candidates provided statistically significant feed conversion benefits in healthy broiler flocks exposed to pathogens present in litter from previous flocks, emulating exposure that may occur in a typical broiler production environment.

PACT Pharma, Inc., a clinical-stage company developing transformational personalized neoTCR-T cell therapies for the eradication of solid tumors, today announced that the company will present at the 39 th Annual J.P. Morgan Healthcare Conference, which is being held virtually, on January 11, 2021 at 7:30 a.m. PT / 10:30 a.

Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, has entered into an employment agreement with a newly hired employee that, among other things, provides for the grant of a non-qualified stock option and of restricted stock units as inducements material to the employee entering into employment with Voyager. The inducement awards wer

Technologies include In-Sleep Target Memory Consolidation Technology, Handheld Skin Quality Optical Coherence Tomography, Handheld Ultrasound System, Measurement Technique for Lumbar Spine X-Ray Images, and AI Decision Support Technology of Fundus Image in Diabetes Mellitus

DermTech, Inc. (Nasdaq: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the closing of its previously announced underwritten public offering of 4,872,881 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase up to 635,593 additional shares, at a price to the public of $29.50 per share. DermTe

Menlo Park, California--(Newsfile Corp. - January 11, 2021) - 180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the “Company”), a clinical-stage biotechnology company with its lead indication in Phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that the Company will present at the Biotech Showcase™ Digital 2021 Conference.

AIM Biotech is participating in Biotech Showcase 2021, where CEO Jim McGorry will share the Company’s plan to commercialize its organ-on-a-chip product line and contract research services.

Vancouver, British Columbia--(Newsfile Corp. - January 11, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) (“Entheon” or the “Company”), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce that it has engaged Mr. Scott Keeney, to serve as a media advisor.

Komodo Health today announced its acquisition of Mavens, a leader in cloud-based technology solutions.